Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe change is a backend revision update (v3.4.1 added, v3.4.0 removed) with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoChange DetectedAdded a Show glossary option and updated metadata labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with a revision note of v3.4.0, while removing the previous capitalization variant and the No FEAR Act data label.SummaryDifference0.1%

- Check16 days agoChange DetectedThe update timestamp label changed from 'Last Update Posted (Estimated)' to 'Last Update Posted'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check23 days agoChange DetectedThe page revision label was updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check44 days agoChange DetectedA consolidated Locations section listing all participating states has been added, and the previous per-state location entries were removed. The page shows Revision: v3.3.3.SummaryDifference1%

- Check53 days agoChange DetectedNew data added: EU CTIS number 2024-512005-87-00 and study completion date 2026-05-01, plus updated last update indicators (2025-11-28, 2025-11). Some older timestamps and the 'Last Update Posted' entry were removed.SummaryDifference0.1%

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.